• Trial Shows Biodesix Assay Predicts Breast Cancer Response to Femara (Genetic Engineering News)

    December 13, 2011 The use of Biodesix’ predictive cancer therapy assay VeriStrat has been validated in a Phase III trial originally carried out to evaluate GlaxoSmithKline’s Tykerb®/Tyverb® (lapatinib) as an addition to Novartis’ Femara® (letrozole) in breast cancer patients. Data from the trial demonstrated that VeriStrat could be used to identify a group of patients with worse progression-free survival (PFS) when treated with Femara alone, independent of Her2 ... Read more
  • Serum Profiling Making Mark on Predictive Medicine (Genetic Engineering News)

    April 4, 2011 Blood is a readily available and rich source of biomarkers that have the potential for use in diagnostics and companion diagnostics development, disease characterization and monitoring, and predictive drug response and toxicity analysis. Serum profiling using a variety of techniques to identify disease- or treatment-related proteins, antibodies, or oligonucleotides is leading to the identification of ... Read more
  • Getting Personal (Clinical Lab Products)

    March 2, 2011 Personalized medicine, one goal of molecular diagnostics that is already being clinically realized, offers the opportunity to treat individuals on a case-by-case basis with greater efficacy and efficiency than ever before. Molecular diagnostics is heading the way of personalized medicine, aiming to help physicians devise particular treatment plans for individuals based on their genetic makeup. “This is ... Read more
  • Biodesix Targeting Pharma for VeriStrat (GenomeWeb)

    January 24, 2011 As Biodesix continues clinical validation and commercialization of its test to predict patient response to therapies for non-small cell lung cancer, it is looking to forge pharmaceutical partnerships to increase adoption of the test. The company is in the midst of conducting a trial in Italy to determine whether the test can determine which NSCLC ... Read more
  • Blood test helps target Roche/OSI lung cancer drug (Reuters)

    August 27, 2010 Blood analysis good at predicting how tumours will respond;  Proteomic test useful when doctors have no tumour tissue LONDON, April 30 (Reuters) – Testing for specific cancer protein markers in lung cancer patients’ blood helps find those more likely to respond to Tarceva, a drug sold by Roche (ROG.VX) and OSI Pharmaceuticals OSIP.O, data showed on ... Read more
  • CBSA BioBreakfast Focuses on Two CO Success Stories of 2009 (Rocky Radar)

    May 21, 2010 CBSA’s May BioBreakfast allowed two of Colorado’s 2009 Bioscience success stories to share their stories.  First up was Paul Beresford of Biodesix, a company playing in the diagnostic space. Dr. Beresford spoke to the attendees about Biodesix’s successful introduction of VeriStrat, a proteomic serum test used in lung cancer. For Customer Support, call: (866) 432-5930 Read more
  • Video Highlights from 2nd European Lung Cancer Conference Feature Biodesix Serum Test

    May 12, 2010 Watch the ELCC video highlights covering topics on tobacco control, translational research in lung cancer, novelties in the management of advanced NSCLC and radiotheraphy techniques.  The highlights, which run for approximately 14 minutes, also present current issues with lung cancer tissue testing. This is followed by a discussion of VeriStrat, Biodesix proteomic serum test for ... Read more
  • Personalized Medicine Coalition Applauds Data Presentations at IASLC/ESMO ELCC

    May 10, 2010 The Personalized Medicine Coalition (PMC) applauds the substantial number of new studies focusing on targeted approaches to the treatment of lung cancer presented at the second joint European Lung Cancer Conference of the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO) in Geneva. “The number of studies ... Read more
  • New Blood Test May Help in the Fight Against Lung Cancer (Queen’s University)

    May 6, 2010 A new blood test could improve the use of a popular lung cancer drug called erlotinib by allowing doctors to select which patients will react positively to the drug. Currently, patients with non-small cell lung cancer receive erlotinib after chemotherapy and other drugs have failed. But erlotinib will only shrink the tumour about 10 per cent ... Read more
  • Biodesix: A New Way to Inform Cancer Treatment Selection (Rocky Radar)

    October 29, 2009 “One data point doesn’t tell you very much in most cases,” comments David Brunel, CEO of Biodesix, a medical diagnostics company based in Broomfield, Colorado. This principle guides Biodesix’s approach to developing diagnostics which aim to identify a patient’s expected response to a particular therapeutic. This story is no longer available from Rocky Radar. For Customer Support, call: ... Read more